# FDA Grants Accelerated Approval to Atacicept (Trutakna) for IgA Nephropathy

> fda · REPORTED · 2026-07-07

On July 7, 2026, the FDA granted accelerated approval to atacicept (Trutakna) for adults with IgA nephropathy, making it the first dual BAFF and APRIL inhibitor cleared for the progressive kidney disease. The Phase 3 ORIGIN-3 trial showed a 45.7% reduction in proteinuria versus 6.8% for standard of care at 36 weeks.

About Vera Therapeutics: Vera Therapeutics is a clinical-stage biopharmaceutical company developing atacicept, a recombinant fusion protein that inhibits two B-cell cytokines (BAFF and APRIL) implicated in IgA nephropathy and other immune-mediated diseases.

- Company: Vera Therapeutics
- Sector: therapeutics
- Primary source: https://lifesciencedaily.news/fda-drug-approval-decisions-to-watch-july-and-august-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.